Skip to main content
Equibles
BHVN logo

BHVN · Biohaven Ltd.

Track BHVN — free

Use BHVN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BHVN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.97 +0.10 (+0.78%) At close · Oct 5
Russell 2000 member Rebalance outlook locked
Market Cap
$2.01B
Shares
151.04M
Volume · Oct 5 1.67M Avg daily vol (3M) 2.63M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.97 Open$12.85 Day$12.45–13.31 52W close$7.79–18.11 Avg vol 30d3.4M Short int20.4M · 13.5% float · 6.5d Short vol36% Last earningsMay 27, 2026 DataSep 2022–Oct 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026
Q4 2021 earnings call transcript
call held Dec 31, 2021

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-17.0%
Trailing year
Short interest
13.5%
Latest settlement · 6.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg −8%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 50%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −17%
trailing
6-month return +24%
trailing
YTD return +15%
this year
Relative strength +13%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $14 › 200d $12 — 50d above 200d
Institutional flow Accumulating
2 of 297 funds reported for Sep 30 · net +604 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
13.54% of float · ▲ +7.6% MoM · 6.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
297 holders — near 3-yr high, broad support
Squeeze score 62
elevated · 0–100
Fundamentals
Fair
EPS growth +26%
Y/Y
Free cash flow $-610.2M
Quant / Vol
risk profile
Very High
Volatility 92%
annualized · 1-yr
Max drawdown −57%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
−8% Bearish
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
50% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $14 › 200d $12 — 50d above 200d
Institutional flow Accumulating
2 of 297 funds reported for Sep 30 · net +604 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
13.54% of float · ▲ +7.6% MoM · 6.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
297 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8 Now $13 · 50% Range high $18
vs 200-day avg +8% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BHVN
Biohaven Ltd.
this stock
$2.01B +14.9% — — 13.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
297
% held
95.5%
Reported
2 of 297
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
56
View
Short & Settlement
Short Interest Rising
Shares short
20.4M
Days to cover
6.5d
Change
+1.4M sh
View
Short Volume
Short vol %
36%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$14
As of
Aug 25, 2026
View
Off-Exchange
Off-exchange %
39.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-738.8M
EPS diluted
$-6.86
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 10, 2026
This year
16
View
Proposed Sales
Value
$459.7K
Shares
11.0K
Filed
Dec 29, 2023
View
Earnings & Events
Webcasts
Last webcast
May 27, 2026
View

Performance

5D 20D 120D MTD YTD
BHVN -2.3% -17.3% +24.2% -2.9% +14.9%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -3.5% -17.9% +12.7% -4.5% +1.3%
Key facts CIK 1935979 CUSIP G1110E107 13F (30d) 7 filings 7 filers Visit website Investor relations